PT93458A - Processo para a preparacao e purificacao de interleuquina-3 humana recombinante das suas muteinas e de composicoes farmaceuticas que as contem - Google Patents

Processo para a preparacao e purificacao de interleuquina-3 humana recombinante das suas muteinas e de composicoes farmaceuticas que as contem

Info

Publication number
PT93458A
PT93458A PT93458A PT9345890A PT93458A PT 93458 A PT93458 A PT 93458A PT 93458 A PT93458 A PT 93458A PT 9345890 A PT9345890 A PT 9345890A PT 93458 A PT93458 A PT 93458A
Authority
PT
Portugal
Prior art keywords
recombinant
muteins
purification
preparation
pharmaceutical compositions
Prior art date
Application number
PT93458A
Other languages
English (en)
Other versions
PT93458B (pt
Inventor
Robert Willem Van Leen
Nicolaas Ludovicus
Maria Persoon
Original Assignee
Gist Brocades Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gist Brocades Nv filed Critical Gist Brocades Nv
Publication of PT93458A publication Critical patent/PT93458A/pt
Publication of PT93458B publication Critical patent/PT93458B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT93458A 1989-03-15 1990-03-15 Processo para a preparacao e purificacao de interleuquina-3 humana recombinante das suas muteinas e de composicoes farmaceuticas que as contem PT93458B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP89200660 1989-03-15
EP89201967 1989-07-25

Publications (2)

Publication Number Publication Date
PT93458A true PT93458A (pt) 1990-11-07
PT93458B PT93458B (pt) 1997-01-31

Family

ID=26121004

Family Applications (1)

Application Number Title Priority Date Filing Date
PT93458A PT93458B (pt) 1989-03-15 1990-03-15 Processo para a preparacao e purificacao de interleuquina-3 humana recombinante das suas muteinas e de composicoes farmaceuticas que as contem

Country Status (17)

Country Link
EP (1) EP0390252B1 (pt)
JP (1) JPH03504561A (pt)
AT (1) ATE140979T1 (pt)
AU (1) AU633891B2 (pt)
CA (1) CA2028827A1 (pt)
DE (1) DE69027948T2 (pt)
DK (1) DK0390252T3 (pt)
ES (1) ES2092486T3 (pt)
FI (1) FI905593A7 (pt)
GR (1) GR3021140T3 (pt)
HU (1) HUT56134A (pt)
IE (1) IE75344B1 (pt)
IL (1) IL93756A (pt)
NO (1) NO179252C (pt)
NZ (1) NZ232913A (pt)
PT (1) PT93458B (pt)
WO (1) WO1990010705A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705362A (en) * 1992-05-25 1998-01-06 Gist-Brocades, N.V. Modified signal sequences
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5463029A (en) * 1992-11-23 1995-10-31 Immunex Corporation Purification of fusion proteins comprising GM-CSF and IL-3
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
ATE238421T1 (de) 1992-11-24 2003-05-15 Searle & Co Interleukin-3 (il-3)-polypeptide mith mehreren mutationen
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
EP1618888B1 (en) * 1993-03-09 2011-01-05 The University Of Rochester Production of human papillomavirus capsid protein and virus-like particles
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
WO1999041382A2 (en) * 1998-02-17 1999-08-19 Hyseq, Inc. A novel interleukin-3 and uses thereof
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
GR871029B (en) * 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
IL84852A (en) * 1986-12-16 1994-06-24 Gist Brocades Nv Molecular cloning and expression of human IL-3
EP0342206A4 (en) * 1987-01-20 1990-09-19 Immunex Corporation Human interleukin-3 proteins

Also Published As

Publication number Publication date
ES2092486T3 (es) 1996-12-01
NO904927L (no) 1990-11-13
AU5264490A (en) 1990-10-09
ATE140979T1 (de) 1996-08-15
IE900937L (en) 1990-09-15
FI905593A0 (fi) 1990-11-12
FI905593A7 (fi) 1990-11-12
AU633891B2 (en) 1993-02-11
EP0390252B1 (en) 1996-07-31
IL93756A0 (en) 1990-12-23
GR3021140T3 (en) 1996-12-31
HU902850D0 (en) 1991-02-28
DE69027948D1 (de) 1996-09-05
JPH03504561A (ja) 1991-10-09
NZ232913A (en) 1992-08-26
NO179252B (no) 1996-05-28
EP0390252A3 (en) 1991-06-19
CA2028827A1 (en) 1990-09-16
WO1990010705A3 (en) 1990-11-01
IE75344B1 (en) 1997-08-27
PT93458B (pt) 1997-01-31
DK0390252T3 (da) 1996-12-09
WO1990010705A2 (en) 1990-09-20
IL93756A (en) 1997-06-10
HUT56134A (en) 1991-07-29
DE69027948T2 (de) 1997-01-30
NO179252C (no) 1996-09-04
EP0390252A2 (en) 1990-10-03
NO904927D0 (no) 1990-11-13

Similar Documents

Publication Publication Date Title
PT93458A (pt) Processo para a preparacao e purificacao de interleuquina-3 humana recombinante das suas muteinas e de composicoes farmaceuticas que as contem
ATE142692T1 (de) Herstellung von hämoglobin und analogen davon durch bakterien oder hefen
NO872988L (no) Pattedyr-interleukin-4.
DE68929551D1 (de) Menschliche DNase
BR8501624A (pt) Polipeptidio ativo fisiologicamente,acido desoxirribonucleido,recombinante aplicavel do dna,microorganismo ou uma cultura de celulas,metodo para a producao de um polipeptidio ativo fisiologicamente,plasmidio e composicao
PT81590A (en) Method of producing a human cdna clone wich expresses biologically active erythropoietin
AU2881389A (en) Human ifn-beta 2/il-6, its purification and use
ATE140965T1 (de) Protein, dna und ihre verwendung
ATE81671T1 (de) Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung.
FI864654A0 (fi) Menetelmä modifioidun ihmisen t-PA-proteiinin valmistamiseksi
FI885807L (fi) Puhdistetun, biologisesti aktiivisen, bakteerien avulla tuotetun rekombinanttisen ihmis- CSF-1:n tuottaminen
CA2062969A1 (en) Recombinantly produced human membrane cofactor protein (mcp)
ES2113338T3 (es) Clonado molecular y expresion de il-3 humano.
PT86276A (en) Method for the production of hybrid proteins
EP0287075A3 (en) Process for the construction of an animal cell line for the production of human beta-interferon
DE3850774D1 (de) Rinder-interleukin-1-alpha.
NO180636C (no) Fremgangsmåte for fremstilling av et rent O-glycosylert IGF-1
ATE164882T1 (de) Verfahren zur herstellung von aktivierten killer- monozyten und verfahren zur überprüfung ihrer tumoriziden aktivität
BR8504700A (pt) Membrana incluindo uma folha elastomera de borracha liquida,processo para sua preparacao,composicao assim obtida bem como emprego da mesma
RU94045922A (ru) Противоопухолевый цитокин, способ его получения, способ его очистки, фармацевтическая композиция на его основе, иммуномодулятор и фактор роста
ATE110112T1 (de) Verfahren und systeme zur herstellung von hiv- antigenen.
ATE145939T1 (de) Mitogen für die glatte muskulatur und dessen kodierende dns
DE68916559D1 (de) Polypeptide und dafür kodierende DNA.

Legal Events

Date Code Title Description
FG3A Patent granted, date of granting

Effective date: 19961023

PC3A Transfer or assignment

Free format text: 19981117 DSM N.V. NL